| P&L Statement | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue | 706 | 1309 | 1341 |
| Cost of Material Consumed | 444 | 1052 | 1062 |
| Change in Inventory | 21 | -68 | -37 |
| Gross Margins | 37.11 | 19.63 | 20.81 |
| Employee Benefit Expenses | 74 | 75 | 69 |
| Other Expenses | 892 | 73 | 67 |
| EBITDA | -725 | 177 | 180 |
| OPM | -102.69 | 13.52 | 13.42 |
| Other Income | 2853 | -1 | 1 |
| Finance Cost | 231 | 98 | 35 |
| D&A | 28 | 25 | 23 |
| EBIT | -753 | 152 | 157 |
| EBIT Margins | -106.66 | 11.61 | 11.71 |
| PBT | 1869 | 52 | 122 |
| PBT Margins | 264.73 | 3.97 | 9.1 |
| Tax | 0 | 0 | 0 |
| PAT | 1869 | 52 | 122 |
| NPM | 264.73 | 3.97 | 9.1 |
| EPS | 123.03 | 3.42 | 7.8 |
| Financial Ratios | 2021 | 2022 | 2023 |
|---|---|---|---|
| Operating Profit Margin | -102.69 | 13.52 | 13.42 |
| Net Profit Margin | 264.73 | 3.97 | 9.1 |
| Earning Per Share (Diluted) | 123.03 | 3.42 | 7.8 |
| Assets | 2021 | 2022 | 2023 |
|---|---|---|---|
| Fixed Assets | 926 | 879 | 820 |
| CWIP | 22 | 26 | 30 |
| Investments | 22 | 15 | 13 |
| Trade Receivables | 274 | 314 | 698 |
| Inventory | 772 | 699 | 681 |
| Other Assets | 346 | 385 | 173 |
| Total Assets | 2362 | 2318 | 2415 |
| Liabilities | 2021 | 2022 | 2023 |
|---|---|---|---|
| Share Capital | 151.92 | 151.92 | 156.48 |
| FV | 10 | 10 | 10 |
| Reserves | 81 | 452 | 681 |
| Borrowings | 1139 | 856 | 850 |
| Trade Payables | 456 | 337 | 266 |
| Other Liabilities | 534.08 | 521.08 | 461.52 |
| Total Liabilities | 2362 | 2318 | 2415 |
| Cash-Flow Statement | 2021 | 2022 | 2023 |
|---|---|---|---|
| PBT | -891 | 52 | 124.6 |
| OPBWC | 154 | 181.64 | 182.17 |
| Change in Receivables | -12 | -43 | -384 |
| Change in Inventories | 30 | 73 | 18 |
| Change in Payables | 0 | 0 | 0 |
| Other Changes | 106 | -96.12 | 226.32 |
| Working Capital Change | 124 | -66.12 | -139.68 |
| Cash Generated From Operations | 278 | 115.52 | 42.49 |
| Tax | 0 | -0.18 | 0 |
| Cash Flow From Operations | 278 | 115.34 | 42.49 |
| Purchase of PPE | -8 | -16 | 2.4 |
| Sale of PPE | 0 | 0 | 0 |
| Cash Flow From Investment | -8 | -10.67 | -1.39 |
| Borrowing | -39 | -6.8 | -6.34 |
| Dividend | 0 | 0 | 0 |
| Equity | 0 | 0 | 0 |
| Others From Financing | -231 | -98.33 | -34.75 |
| Cash Flow from Financing | -270 | -105.13 | -41.09 |
| Net Cash Generated | 0 | -0.46 | 0.01 |
| Cash at the Start | 3 | 3 | 2.76 |
| Cash at the End | 3 | 2.54 | 2.77 |
Arch Pharmalabs Limited is an Indian public company engaged in the manufacturing of active pharmaceutical ingredients (APIs), intermediates and providing contract research and manufacturing services (CRAMS/CDMO) to both domestic and global pharmaceutical companies.(archpharmalabs.com) Incorporated in 1993 (CIN U24231MH1993PLC150891) and headquartered in Mumbai, Maharashtra, the company boasts seven to nine GMP-compliant multipurpose manufacturing facilities across India and a diversified product portfolio spanning more than 120 products—including APIs and intermediates across therapeutic segments such as antibiotics, lipid-lowering agents, oncology, anti-infectives and CNS agents.(archpharmalabs.com) According to latest publicly available figures, in FY2023 the company reported revenue of around ?1,344 crore and a profit after tax of approximately ?122 crore, reflecting improved margins and a recovery from earlier losses.(Altius Investech)
From the perspective of its unlisted shares, Arch Pharmalabs remains unlisted on major Indian stock exchanges.(The Company Check) Being an unlisted public company, investment in its shares means facing typical unlisted-equity characteristics: limited liquidity, fewer mandated disclosures compared to listed peers, and dependence on private transactions or specialized platforms for buying and selling. For example, unlisted-share information platforms note the company’s moderate debt-equity ratio (~1.0×), return on equity in the ~14-15% range, and an estimated unlisted market valuation in the vicinity of ?1,300-?1,400 crore, which suggests a price-to-earnings ratio of approximately 10-16× based on recent earnings.(unlistedhub.in) For potential investors, this presents both an opportunity and a risk: the company operates in a high-growth segment (global API/CDMO outsourcing, regulatory tailwinds) and appears to have improving financials, yet the lack of listing means exit timing is uncertain and valuation may be driven more by sentiment than by publicly traded market comparables.
1. What is the first step to buy Arch Pharmalabs Limited Unlisted Shares?
The first step is to confirm your booking of Arch Pharmalabs Limited Unlisted Shares with us at an agreed-upon trading price.
2. What documents are required to purchase these unlisted shares?
You will need to provide your Client Master Report (CMR), your PAN Card, and a Cancelled Cheque.
3. Why are these specific documents (CMR, PAN, Cancelled Cheque) required?
These are mandatory KYC (Know Your Customer) documents required as per SEBI (Securities and Exchange Board of India) regulations for share transactions.
4. What if I don't have a Client Master Report (CMR)?
You should contact your broker, who can provide you with your Client Master Report.
5. When do I need to provide a Cancelled Cheque?
A Cancelled Cheque is required if you are not transferring funds from the bank account that is mentioned in your Client Master Report (CMR).
6. How will I know where to transfer the payment for the shares?
We will provide you with the necessary bank details once your booking and documentation are in order.
7. What payment methods are accepted for buying the shares?
Payment must be made via RTGS (Real-Time Gross Settlement), NEFT (National Electronic Funds Transfer), IMPS (Immediate Payment Service), or Cheque Transfer.
8. Are cash deposits allowed for payment?
No, cash deposits are strictly not permitted. Payments must be made through official banking channels like RTGS, NEFT, IMPS, or Cheque Transfer.
9. Is there any specific requirement for the bank account used for payment?
Yes, the payment must be made from the same bank account in which the shares are intended to be credited. This ensures compliance and smooth processing.
10. What happens after I confirm booking, provide documents, and make payment?
Once all steps are completed – booking confirmed, KYC documents submitted, and payment successfully transferred from the correct account – the shares will be processed for credit to your demat account.